Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome

Abstract

A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo[3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension. In a combination drug which also comprise a soy protein, and/or soy fiber and/or at least one isoflavone these substances act synergistically and such combination drugs are highly useful both prophylacticly or directly in the treatment of e.g. the metabolic syndrome and obesity and has due to the self-regulatory effect a widespread applicability as a dietary supplementation.

1 . A pharmaceutically acceptable composition comprising a substance including a bicyclo[3.2.1]octan in a double ring system having a basic chemical skeleton of kaurene structure with the structural formula II  
     
       
         
         
             
             
         
       
     
   
   
       2 . A composition according to  claim 1  wherein the chemical structure having the structural formula II provides the substance with the capability of enhancing or potentiating the secretion of insulin.  
   
   
       3 . A composition according to  claim 1  wherein the substance is isolatable from a plant source.  
   
   
       4 . A method of treating non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome which comprises administering to a subject in need thereof a therapeutically effective amount of the composition of  claim 1 .  
   
   
       5 . The method of  claim 4 , wherein the substance is selected from the group consisting of steviol, isosteviol, glucosilsteviol, gymnemic acid, steviolbioside, stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E and Dulcoside A.  
   
   
       6 . The method of  claim 4  wherein the subject is afflicted with non-insulin dependent diabetes mellitus and wherein insulin secretion is stimulated in the subject, the stimulation of the insulin secretion being initiated by the presence of a plasma glucose concentration of 6 mmol/l or larger.  
   
   
       7 . A method of reducing the glucagon concentration in the blood which comprises administering, to a subject in need thereof, a glucagon-reducing amount of the composition of  claim 1 .  
   
   
       8 . A method of lowering the blood pressure which comprises administering, to a subject in need thereof, a blood pressure reducing amount of the composition of  claim 1 .  
   
   
       9 . The composition of  claim 1 , further comprising the claims at least one soy protein.  
   
   
       10 . The composition of  claim 9 , further comprising at least one isoflavone.  
   
   
       11 . The method of  claim 4 , said composition further comprising at least one soy protein.  
   
   
       12 . A method for the treatment of obesity, overweight or dyslipidemia, which comprises administering to a subject in need thereof a therapeutically effective amount of the composition of  claim 1 .  
   
   
       13 . A method of dietary supplementation which comprises supplementing the diet of a subject with a composition comprising a double ring system having a basic chemical skeleton of kaurene structure with the structural formula II  
     
       
         
         
             
             
         
       
     
   
   
       14 . The method of  claim 13  wherein the dietary supplementation further comprises supplementation with at least one soy protein and/or at least one isoflavone.  
   
   
       15 . The method of  claim 13  wherein the substance is isolatable from a plant source.  
   
   
       16 . The method of  claim 13  wherein the substance is selected from the group consisting of steviol, isosteviol, glucosilsteviol, gymnemic acid, steviolbioside, stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E and Dulcoside A.